QHSLab (USAQ)
OTHER OTC:USAQ
Want to see USAQ full AI Analyst Report?
USAQ Stock Chart & Stats
$0.49
-$0.04(-14.29%)
At close: 4:00 PM EST
$0.49
-$0.04(-14.29%)
Day’s Range― - ―
52-Week Range$0.08 - $1.14
Previous CloseN/A
Volume38.37K
Average Volume (3M)6.57K
Market Cap
$9.02M
Enterprise Value$6.17M
Total Cash (Recent Filing)$636.16K
Total Debt (Recent Filing)$20.00K
Price to Earnings (P/E)15.0
Beta0.89
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding15,032,788
10 Day Avg. Volume9,209
30 Day Avg. Volume6,568
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.21
Price to Sales (P/S)2.54
P/FCF Ratio38.43
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue2.29
Enterprise Value/Gross Profit3.41
Enterprise Value/Ebitda7.85
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
2025 Revenue Growth And Margin ExpansionSustained revenue acceleration and a very high gross margin indicate the business can scale contribution margins and absorb SG&A, improving long-term profitability potential. Durable margin expansion supports reinvestment capacity and resilience to pricing pressure in medical services and digital health markets.
Major Debt Reduction And Capital Structure SimplificationMaterial deleveraging reduces fixed financing costs and lowers solvency risk, freeing cash for R&D and commercialization. A simpler balance sheet improves access to capital and strategic optionality, making the company structurally more able to fund growth without heavy interest burdens.
Diversified Service/product Revenue GrowthBroadening revenue mix across services, therapeutics and digital tools reduces concentration risk and increases cross-sell potential. Early reimbursement for Q-Cog and strong program growth create durable commercial channels within primary care and population health markets.
Bears Say
Weak Cash Conversion And Historical Negative Cash FlowEarnings have not reliably converted to cash historically, which risks liquidity and the ability to fund operations organically. Persistently low cash conversion can mask earnings quality and leave the company reliant on external financing if working-capital or reimbursement timing shifts.
Balance-sheet Improvement Driven By One-time Equity Issuance/dilutionRecapitalization via share issuance materially improved reported leverage but diluted existing shareholders and may not reflect recurring operating progress. One-off fixes can hide structural profitability gaps and raise future governance or investor-return concerns.
Small Scale And Volatile Operating PerformanceLimited scale and erratic operating margins constrain operational leverage and raise execution risk for commercial expansion. Small team and low revenues make sustaining sales, regulatory, and reimbursement initiatives harder without consistent cash generation or scaled sales infrastructure.
QHSLab News
USAQ FAQ
What was QHSLab’s price range in the past 12 months?
QHSLab lowest stock price was $0.08 and its highest was $1.14 in the past 12 months.
What is QHSLab’s market cap?
QHSLab’s market cap is $9.02M.
When is QHSLab’s upcoming earnings report date?
QHSLab’s upcoming earnings report date is May 18, 2026 which is in 26 days.
How were QHSLab’s earnings last quarter?
QHSLab released its earnings results on Mar 31, 2026. The company reported $0.032 earnings per share for the quarter, beating the consensus estimate of N/A by $0.032.
Is QHSLab overvalued?
According to Wall Street analysts QHSLab’s price is currently Overvalued.
Does QHSLab pay dividends?
QHSLab does not currently pay dividends.
What is QHSLab’s EPS estimate?
QHSLab’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does QHSLab have?
QHSLab has 15,032,788 shares outstanding.
What happened to QHSLab’s price movement after its last earnings report?
QHSLab reported an EPS of $0.032 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 8.07%.
Which hedge fund is a major shareholder of QHSLab?
Currently, no hedge funds are holding shares in USAQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
QHSLab
QHSLab, Inc., a medical device technology and software as a service (SaaS) company, focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It also develops digital therapeutics and point of care solutions to support remote patient monitoring, address chronic care, and preventive medicine. In addition, the company provides quality health score lab expert system (QHSLab), a cloud-based SaaS system, which provides physicians and healthcare organizations with the ability to capture and store patient information electronically in a secure database; and distributes AllergiEnd, a diagnostic related product and allergen immunotherapy treatments to primary care physicians. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. QHSLab, Inc. has a strategic alliance with Medical License Factory, LLC. The company was incorporated in 1983 and is based in West Palm Beach, Florida.